Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04064840
Recruiting Phase 3

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

NCT04064840 · tracked via the Priya Life Science China tracker
Sponsor
The University of Hong Kong
Phase
Phase 3
Started
2019-09-01
Last updated
2026-05-15

Condition(s) studied

Subfertility

Investigational drug(s) / intervention(s)

IVF: Decapeptyl and hCGFET: DecapeptylIVF: hCG and normal salineFET: Normal Saline

IVF: Decapeptyl and hCG: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

FET: Decapeptyl: On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

IVF: hCG and normal saline: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

FET: Normal Saline: On the day of FET, normal saline will be injected subcutaneously.

Study summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
42 Years
Healthy volunteers
No
IVF Inclusion criteria: \- Women aged \<43 years at the time of IVF treatment Exclusion criteria: * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated * Women at risk of OHSS FET Inclusion criteria: * Women aged \<43 years at the time of IVF treatment * Replacing early cleavage embryos or blastocysts after thawing * FET in natural cycles Exclusion criteria: * Frozen early cleavage embryos thawed and cultured to blastocysts prior to transfer as requested by the patient * Preimplantation genetic diagnosis treatment * Use of donor oocytes or donor embryos * Hydrosalpinx shown on pelvic scanning and not surgically treated

Primary outcome measure(s)

  • Live birth rate — after 22 weeks
    delivery after 22 weeks

Trial sites (1)

FacilityCityRegionStatus
Department of Obstetrics and Gynaecology Hong Kong Hong Kong Recruiting

More The University of Hong Kong trials in China

The "Quit-for-Kids" Project: to Increase Abstinence and Protect Children From Tobacco Smoke Exposure Recruiting
Testing the Performance of Smartphones and Their Accessories in Detecting Irregularly Irregular Heart Rhythm Enrolling by invitation
Role of Exercise in PRISm and Subsequent Development of COPD Recruiting
Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET Recruiting
Pleurodesis in Small-bore Chest Tube Starting soon

Other trials for the same condition

Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04064840 on ClinicalTrials.gov ↗ ← All trials in China